From Niagen Bioscience’s (Chromadex) presentation earlier this month at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference:

CEO Rob Fried:

“…also recently, we completed a study with Harvard, a small study.

It was only 58 participants on Long COVID — which is a very important condition that many people who have had COVID…

And they recovered from COVID technically, but they still have the fatigue, or they still have the cognition issues or the depression associated with it.

And they haven’t been able to find a resolution.

And that study was done with Harvard and was completed recently.

The results of that have also not been made public.

But these are just 2 recent examples of actual studies on important conditions and indications included in those 40 (clinical studies on Niagen NR)”

Related:

  • FAQs on the Potential for Treating Long COVID with Vitamin Supplement Nicotinamide Riboside “NR” (Link)
  • Nicotinamide Riboside “NR” (FAQs) (Consumer Reviews)

FOLLOW us on Twitter @RaisingNAD